• Possible Therapeutic Vaccines for Canine Myasthenia Gravis: Implication for the Human Disease and Associated Fatigue

Galin, F. Shawn , Cheryl L. Chrisman, James R. Cook Jr., Likang Xu, Patricia L. Jackson, Brett D. Noerager, Nathaniel M. Weathington and J. Edwin Blalock
Brain, Behavior, and Immunity, Volume 21, Issue 3, March 2007, Pages 323-331

http://dx.doi.org/10.1016/j.bbi.2006.10.001

• Molecular recognition theory and sense-antisense interaction: therapeutic applications in autoimmunity

Hardison MT and J. Edwin Blalock
Front Biosci (Elite Ed). 2012 Jan 1;4:1864-70. doi: 10.2741/508. PMID: 22202003; PMCID: PMC4107873.

https://pubmed.ncbi.nlm.nih.gov/22202003/

• Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network

Weathington, Nathaniel M. and J. Edwin Blalock
Expert Review of Vaccines, Vol. 2, No. 1, Pages 61-73, 2003

https://pubmed.ncbi.nlm.nih.gov/12901598/

• The Role of Adjuvants in the Efficacy of a Peptide vaccine for Myasthenia Gravis

McAnally, James L. , Likang Xu, Matteo Villain and J.Edwin Blalock
Exp Biol Med Vo. 226(4): 307-311, 2001

https://doi.org/10.1177/153537020122600407

• Prevention and Reversal of Experimental Autoimmune Myasthenia Gravis by a Monoclonal Antibody against Acetylcholine Receptor-Specific T Cells

Xu, L., M. Villain, F.S. Galin, S. Araga, and J.E. Blalock.
Cellular Immunology 208, 107-114, 2001

http://dx.doi.org/10.1006/cimm.2001.1777

• A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help

Araga, Shigeru , Likang Xu, Kenji Nakashima, Matteo Villain and J. Edwin Blalock
FASEB J. 14: 185-196, 2000

http://www.fasebj.org/cgi/reprint/14/1/185.pdf

• Prevention of Experimental Autoimmune Myasthenia Gravis by a Monoclonal Antibody to a Complementary Peptide for the Main Immunogenic Region of the Acetylcholine Receptor

Araga, S., F.S. Galin, M. Kishimoto, A. Adachi, and J.E. Blalock.
The Journal of Immunology, 157: 386-392, 1996

http://www.jimmunol.org/cgi/reprint/157/1/386.pdf

• Use of Complementary Peptides and Their Antibodies in B-Cell-Mediated Autoimmune Disease: Prevention of Experimental Autoimmune Myasthenia Gravis with a Peptide Vaccine

Araga, S. and J.E. Blalock.
IMMUNOMETHODS 5, 130-135, 1994

http://dx.doi.org/10.1006/immu.1994.1047

• Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor

Araga, S., R.D. LeBoeuf and J.E. Blalock.
Proc. Natl. Acad. Sci. USA Vol. 90 Immunology, 8747-8751, 1993

http://www.pnas.org/cgi/content/abstract/90/18/8747